Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
QDEL Catalyst Timeline
Dated clinical, regulatory and corporate events for QuidelOrtho Corporation
Past FDA Catalysts and PDUFA Decisions
How QDEL actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Drug Pipeline Intelligence
No drug pipeline
QuidelOrtho Corporation is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every QDEL program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Siegrist Jonathan PhilipOfficer (EVP of R&D & CTO) | Option | 18,657 32,076 held | $0.00 | 10/15/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in QDEL
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| SOLEUS CAPITAL MANAGEMENT, L.P. | 0 % (-100 %) | 210.80 K | 20.00 K | -73.33% ( -55.00 K) |
Ownership Trends
QDEL Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How QDEL ranks across every disease it competes in
QDEL News
QuidelOrtho Reports Third Quarter 2026 Financial Results
QuidelOrtho reported a 12% decline in total revenue for Q3 2026, totaling $619 million. Despite challenges in China and a weaker respiratory season, the company noted a 2% revenue growth when excluding certain segments. A new cost transformation program is expected to yield over $80 million in annual savings starting in 2027.
Read more →Transforming Data Into Actionable Insights in the Lab
QuidelOrtho Corporation has released episode 62 of its Science Bytes podcast, focusing on AI and informatics in laboratory operations. The episode discusses the need for data integration to enhance clinical decision-making and addresses workforce challenges in clinical laboratories. Rodney Guzman, Vice President of Software Engineering, shares insights on transforming lab data into actionable clinical knowledge.
Read more →QuidelOrtho to Report Third Quarter 2026 Financial Results on November 3, 2026
QuidelOrtho Corporation will release its financial results for Q3 2026 on November 3, 2026, after market close. A conference call and webcast will follow to discuss these results. The event will be accessible via the company's Investor Relations page. QuidelOrtho focuses on advancing diagnostic solutions for improved patient outcomes.
Read more →QuidelOrtho Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
QuidelOrtho Corporation has announced the approval of equity awards under its 2026 Inducement Plan for two newly hired non-executive employees. The grants consist of restricted stock units (RSUs) totaling 50,323 shares, which will vest in equal annual installments over three years. This initiative aligns with Nasdaq Listing Rule 5635(c)(4) to attract new talent.
Read more →QuidelOrtho Appoints Sanjeev Sharma as Vice President of Investor Relations
QuidelOrtho Corporation has appointed Sanjeev Sharma as Vice President of Investor Relations, effective September 28, 2026. Sharma has over 20 years of experience in investor relations and corporate strategy, previously serving at Teva Pharmaceuticals. His expertise is expected to enhance communication with the investment community and support QuidelOrtho's strategic priorities.
Read more →Early Intervention Aids Emergency Medicine Teams in Identifying and Personalizing Sepsis Treatment
QuidelOrtho Corporation's latest podcast episode discusses strategies to lower sepsis rates in emergency medicine. Hosted by Josh Casey, the episode features Chris Sanchez, who shares insights on the importance of swift diagnosis and the use of serial procalcitonin testing. These strategies aim to improve treatment decisions and patient outcomes in critical care settings.
Read more →Faster Answers, Better Decisions: ADLM 2026 Highlights
QuidelOrtho Corporation's latest Science Bytes podcast episode highlights key insights from the 2026 ADLM Annual Conference. Experts discuss advancements in molecular diagnostics, including ultra-fast RT-PCR technology and the role of procalcitonin in antibiotic stewardship. The episode emphasizes the importance of rapid, actionable information for clinicians to improve patient outcomes.
Read more →QuidelOrtho Reports Second Quarter 2026 Financial Results
QuidelOrtho Corporation reported a 3% increase in total revenue for Q2 2026, driven by growth in Labs and Point of Care segments. However, the company experienced a GAAP net loss of $93 million and revised its full-year financial guidance downward due to challenges in the Chinese market and a softer global respiratory environment. Despite these setbacks, the company remains committed to improving cash conversion and strengthening its balance sheet.
Read more →QuidelOrtho to Report Second Quarter 2026 Financial Results
QuidelOrtho Corporation will announce its financial results for the second quarter of 2026 on August 6, 2026. Following the announcement, a conference call will take place to discuss the results. Interested parties can access the call through the company's Investor Relations webpage. QuidelOrtho continues to focus on advancing diagnostic solutions.
Read more →Beyond Fentanyl: How the Drug Crisis Is Changing
QuidelOrtho Corporation's latest podcast episode discusses the evolving drug overdose crisis, highlighting a decline in overdose deaths while addressing ongoing challenges. The episode features insights on counterfeit medications, polysubstance use, and emerging synthetic opioids. It emphasizes the importance of collaboration between laboratories and emergency departments to enhance toxicology testing and patient care.
Read more →QuidelOrtho Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
QuidelOrtho Corporation announced the approval of an Inducement Grant of 356,555 restricted stock units (RSUs) to Micah Young, the new Chief Financial Officer. This grant, approved by the Compensation Committee, is part of the 2026 Inducement Plan and aims to attract talent in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over three years, contingent on Mr. Young's continued employment.
Read more →QuidelOrtho Appoints Micah Young as Chief Financial Officer
QuidelOrtho Corporation has appointed Micah Young as Chief Financial Officer, effective July 6, 2026. Young succeeds Joseph M. Busky, who will assist in the transition. Young has extensive experience in medical technology finance and aims to enhance profitability and shareholder value at QuidelOrtho.
Read more →QuidelOrtho and Allo Hope Foundation Join Forces to Advance Education, Connection and Early Testing for Alloimmunized Pregnancies
QuidelOrtho and the Allo Hope Foundation have announced a collaboration to enhance prenatal care for women facing maternal red blood cell alloimmunization. This partnership aims to provide education, early testing, and improved connections between healthcare providers and patients. The initiative seeks to address gaps in care, particularly for underserved populations, and will produce educational materials for families and lab technicians.
Read more →When Blood Compatibility Becomes a Pregnancy Risk
QuidelOrtho Corporation has released a podcast episode discussing hemolytic disease of the fetus and newborn (HDFN), emphasizing the impact of maternal alloimmunization. The episode highlights the importance of awareness, timely diagnostics, and coordinated care to improve outcomes. Despite advancements, significant gaps in understanding and care persist, affecting patient management.
Read more →QuidelOrtho to Participate in Upcoming June 2026 Investor Conferences
QuidelOrtho Corporation announced its participation in two upcoming investor conferences in June 2026. The management team will present at the William Blair 46th Annual Growth Stock Conference and engage in a fireside chat at the Jefferies Global Healthcare Conference. Interested parties can access the events via the company's Investor Relations page.
Read more →QuidelOrtho Reports First Quarter 2026 Financial Results
QuidelOrtho Corporation reported its first-quarter financial results for 2026, highlighting a weaker respiratory season and disruptions in key markets. Despite these challenges, the company remains optimistic about its growth prospects, particularly following its acquisition of LEX Diagnostics and the launch of new products. The company has updated its financial guidance for the year, factoring in current market dynamics.
Read more →Understanding and Addressing Syphilis Trends - and What's Being Missed
QuidelOrtho Corporation's latest podcast episode discusses the concerning rise in congenital syphilis cases in the U.S., despite a decline in early-stage infections. Hosted by Josh Casey, the episode features insights from Andrea Ott-Vasconi on CDC data and emphasizes the need for improved diagnostic strategies and healthcare workflows. The discussion highlights missed screening opportunities and actionable steps to enhance prenatal care.
Read more →QuidelOrtho Corporation Completes Acquisition of LEX Diagnostics
QuidelOrtho Corporation has successfully acquired LEX Diagnostics for approximately $100 million, enhancing its molecular diagnostics capabilities. The LEX VELO System, which has received FDA clearance, offers rapid RT-PCR testing for Influenza A, Influenza B, and COVID-19. The company plans to launch this system commercially in the U.S. later this year, aiming to improve patient outcomes through faster diagnostics.
Read more →QuidelOrtho Announces Preliminary Revenue for the First Quarter 2026 and Provides Update on Full-Year 2026 Guidance
QuidelOrtho Corporation announced preliminary revenue of $615-$620 million for Q1 2026, affected by a weaker respiratory season and slower sales in China. The company anticipates negative free cash flow for the first half of 2026 but expects to achieve its full-year financial guidance. A conference call to discuss detailed results is scheduled for May 5, 2026.
Read more →Nathaniel Sisitsky Joins QuidelOrtho as Chief Legal Officer
QuidelOrtho Corporation has appointed Nathaniel Sisitsky as its new Chief Legal Officer, effective March 23, 2026. Sisitsky, who has over 25 years of experience in legal and governance roles, succeeds Michelle Hodges, who is retiring. He aims to support the company's mission of advancing diagnostics and improving patient care.
Read more →